Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-01-27 6:01 pm Sale | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.9% | -2,491,141 (-63.38%) | View |
| 2022-02-11 4:19 pm Sale | 13G | Viridian Therapeutics, Inc. VRDN | Ally Bridge MedAlpha Master Fund L.P. | 604,774 2.8% | -325,205 (-34.97%) | View |
| 2022-02-11 4:17 pm Sale | 13G | Cogent Biosciences, Inc. COGT | Ally Bridge MedAlpha Master Fund L.P. | 1,501,591 3.8% | -121,000 (-7.46%) | View |
| 2022-02-11 4:17 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 3,930,520 6.3% | 897,395 (+29.59%) | View |
| 2021-02-12 4:15 pm Purchase | 13G | Cogent Biosciences, Inc. COGT | Ally Bridge MedAlpha Master Fund L.P. | 1,622,591 5.1% | 1,622,591 (New Position) | View |
| 2021-01-07 07:36 am Purchase | 13G | Viridian Therapeutics Inc. MGEN | Ally Bridge MedAlpha Master Fund L.P. | 929,979 9.99% | 929,979 (New Position) | View |
| 2020-12-18 4:20 pm Purchase | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 3,033,125 5.4% | 3,033,125 (New Position) | View |